Enanta Pharmaceuticals Inc (ENTA)

[willyw]

EASL ABBVIE/ENTA presentation

Enanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The International Liver Congress™ 2015

http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2040086

(visit the link for the complete story. ~W)

" The first ten patients, or 100 percent, who have reached post-treatment week four to date (n=10 of 20 enrolled) achieved SVR4 (n=10/10).1 The RUBY-I study was presented as a late-breaker today at The International Liver Congress™ (ILC) 2015, the 50th annual meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. "

=================
My commentary: MRK is pressing for gains in HCV, and their efficacy is good, but perhaps not quite competitive w/ currently approved therapies.
MRK is pressing for niche specialty subgroups groups, but both Gilead and Abbvie will continue to do post approval trials that will serve to undermine any perceived MRK therapy advantages.